Doxycycline anhydrous
As of the edition of 20 October 2026, Doxycycline anhydrous is a small molecule: marketed, first approved in 1968 (ES); acts on MMP1, MMP13 and MMP7 and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Vibramycin
- First approved
- 1 September 1968 (ES)
- Approvals on record
- 32 in 4 regions
- Holder of the most recent approval
- Chartwell Rx Sciences; 9 holders in all
- Registered trials
- 228, 23 stopped early
- Disease areas
- Infections; Skin and connective tissue; Lungs and airways; Urinary and reproductive; Cancer; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
4 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product4 company-target rows are on route B because of Doxycycline anhydrous.
See the 4 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 46 | 26 | 9 | 5 |
| Phase 1 | 20 | 16 | 2 | 1 |
| Phase 2 | 66 | 34 | 14 | 12 |
| Phase 3 | 40 | 22 | 3 | 4 |
| Phase 4 | 56 | 40 | 7 | 1 |
| All trials | 228 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| CollaGenex Pharmaceuticals | Later holder and Lead sponsor of trials | 1998 to now |
| Galderma | Acquired holder | 2008 to now |
| Pfizer | Applicant, Acquired holder and Lead sponsor of trials | 2008 to now |
| Aqua Therapeutics | Later holder | 2014 to now |
| Chartwell Pharma Nda B2 | Later holder | 2018 to now |
| Chartwell Rx Sciences | Acquired holder | 2020 to now |
| Den-Mat | Acquired holder | 2020 to now |